Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes
We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n = 8; BCR-JAK2, n = 1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n = 9). On ruxolitinib (median 24 months, range 2-36 months), a...
Ausführliche Beschreibung
Autor*in: |
Schwaab, Juliana - 1982- [verfasserIn] Naumann, Nicole - 1988- [verfasserIn] Lübke, Johannes - 1996- [verfasserIn] Jawhar, Mohamad - 1986- [verfasserIn] Somervaille, Tim C.P. [verfasserIn] Williams, Mark S. [verfasserIn] Frewin, Rebecca [verfasserIn] Jost, Philipp J. [verfasserIn] Lichtenegger, Felix S. [verfasserIn] La Rosée, Paul [verfasserIn] Storch, Nicola [verfasserIn] Haferlach, Torsten [verfasserIn] Horny, Hans-Peter [verfasserIn] Fabarius, Alice - 1965- [verfasserIn] Haferlach, Claudia [verfasserIn] Burchert, Andreas [verfasserIn] Hofmann, Wolf-Karsten - 1967- [verfasserIn] Cross, Nicholas C.P. [verfasserIn] Hochhaus, Andreas [verfasserIn] Reiter, Andreas - 1964- [verfasserIn] Metzgeroth, Georgia - 1972- [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2020 |
---|
Anmerkung: |
12 April 2020 First published: 12 April 2020 |
---|---|
Umfang: |
10 |
Übergeordnetes Werk: |
Enthalten in: American journal of hematology - New York, NY : Wiley-Liss, 1976, 95(2020), 7 vom: Apr., Seite 824-833 |
---|---|
Übergeordnetes Werk: |
volume:95 ; year:2020 ; number:7 ; month:04 ; pages:824-833 ; extent:10 |
Links: |
---|
DOI / URN: |
10.1002/ajh.25825 |
---|
Katalog-ID: |
1786601257 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | 1786601257 | ||
003 | DE-627 | ||
005 | 20230105143119.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220120s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/ajh.25825 |2 doi | |
035 | |a (DE-627)1786601257 | ||
035 | |a (DE-599)KXP1786601257 | ||
035 | |a (OCoLC)1295679705 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
100 | 1 | |a Schwaab, Juliana |d 1982- |e verfasserin |0 (DE-588)1051912687 |0 (DE-627)787019399 |0 (DE-576)407558764 |4 aut | |
245 | 1 | 0 | |a Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes |c Juliana Schwaab, Nicole Naumann, Johannes Luebke, Mohamad Jawhar, Tim C.P. Somervaille, Mark S. Williams, Rebecca Frewin, Philipp J. Jost, Felix S. Lichtenegger, Paul La Rosée, Nicola Storch, Torsten Haferlach, Hans-Peter Horny, Alice Fabarius, Claudia Haferlach, Andreas Burchert, Wolf-Karsten Hofmann, Nicholas C.P. Cross, Andreas Hochhaus, Andreas Reiter, Georgia Metzgeroth |
264 | 1 | |c 2020 | |
300 | |a 10 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a 12 April 2020 | ||
500 | |a First published: 12 April 2020 | ||
520 | |a We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n = 8; BCR-JAK2, n = 1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n = 9). On ruxolitinib (median 24 months, range 2-36 months), a complete hematologic response (CHR) and complete cytogenetic response (CCR) was achieved by five of nine and two of nine patients, respectively. However, ruxolitinib was stopped in eight of nine patients because of primary resistance (n = 3), progression (n = 3) or planned allogeneic stem cell transplantation (allo SCT, n = 2). At a median of 36 months (range 4-78 months) from diagnosis, five of nine patients are alive: four of six patients after allo SCT and one patient who remains on ruxolitinib. In ETV6-ABL1 positive patients, a durable CHR was achieved by four of nine patients (imatinib with one of five, nilotinib with two of three, dasatinib with one of one). Because of inadequate efficacy (lack of hematological and/or cytogenetic/molecular response), six of nine patients (imatinib, n = 5; nilotinib, n = 1) were switched to nilotinib or dasatinib. At a median of 23 months (range 3-60 months) from diagnosis, five of nine patients are in CCR or complete molecular response (nilotinib, n = 2; dasatinib, n = 2; allo SCT, n = 1) while two of nine patients have died. We conclude that (a) responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and (b) nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6-ABL1 positive patients. | ||
700 | 1 | |a Naumann, Nicole |d 1988- |e verfasserin |0 (DE-588)1138951838 |0 (DE-627)896569624 |0 (DE-576)49279314X |4 aut | |
700 | 1 | |a Lübke, Johannes |d 1996- |e verfasserin |0 (DE-588)1189769867 |0 (DE-627)1668483645 |4 aut | |
700 | 1 | |a Jawhar, Mohamad |d 1986- |e verfasserin |0 (DE-588)1046172905 |0 (DE-627)775847747 |0 (DE-576)399437061 |4 aut | |
700 | 1 | |a Somervaille, Tim C.P. |e verfasserin |4 aut | |
700 | 1 | |a Williams, Mark S. |e verfasserin |4 aut | |
700 | 1 | |a Frewin, Rebecca |e verfasserin |4 aut | |
700 | 1 | |a Jost, Philipp J. |e verfasserin |4 aut | |
700 | 1 | |a Lichtenegger, Felix S. |e verfasserin |4 aut | |
700 | 1 | |a La Rosée, Paul |e verfasserin |4 aut | |
700 | 1 | |a Storch, Nicola |e verfasserin |4 aut | |
700 | 1 | |a Haferlach, Torsten |e verfasserin |4 aut | |
700 | 1 | |a Horny, Hans-Peter |e verfasserin |4 aut | |
700 | 1 | |a Fabarius, Alice |d 1965- |e verfasserin |0 (DE-588)1037001281 |0 (DE-627)751728314 |0 (DE-576)390896667 |4 aut | |
700 | 1 | |a Haferlach, Claudia |e verfasserin |4 aut | |
700 | 1 | |a Burchert, Andreas |e verfasserin |4 aut | |
700 | 1 | |a Hofmann, Wolf-Karsten |d 1967- |e verfasserin |0 (DE-588)114154635 |0 (DE-627)691208751 |0 (DE-576)351568336 |4 aut | |
700 | 1 | |a Cross, Nicholas C.P. |e verfasserin |4 aut | |
700 | 1 | |a Hochhaus, Andreas |e verfasserin |4 aut | |
700 | 1 | |a Reiter, Andreas |d 1964- |e verfasserin |0 (DE-588)172629551 |0 (DE-627)697563766 |0 (DE-576)133488594 |4 aut | |
700 | 1 | |a Metzgeroth, Georgia |d 1972- |e verfasserin |0 (DE-588)1051897661 |0 (DE-627)786986832 |0 (DE-576)407534075 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t American journal of hematology |d New York, NY : Wiley-Liss, 1976 |g 95(2020), 7 vom: Apr., Seite 824-833 |h Online-Ressource |w (DE-627)302923349 |w (DE-600)1492749-4 |w (DE-576)094060002 |x 1096-8652 |7 nnns |
773 | 1 | 8 | |g volume:95 |g year:2020 |g number:7 |g month:04 |g pages:824-833 |g extent:10 |
856 | 4 | 0 | |u https://doi.org/10.1002/ajh.25825 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825 |x Verlag |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ILN_2011 | ||
912 | |a ISIL_DE-16 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_266 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_647 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2119 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2472 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
912 | |a GBV_ILN_2013 | ||
912 | |a GBV_ILN_2403 | ||
912 | |a GBV_ILN_2013 | ||
912 | |a ISIL_DE-16-250 | ||
912 | |a GBV_ILN_2403 | ||
912 | |a ISIL_DE-LFER | ||
951 | |a AR | ||
952 | |d 95 |j 2020 |e 7 |c 4 |h 824-833 |g 10 | ||
980 | |2 2011 |1 01 |x DE-16 |b 4039864360 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 20-01-22 | ||
980 | |2 2013 |1 01 |x DE-16-250 |b 4045645756 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 27-01-22 | ||
980 | |2 2403 |1 01 |x DE-LFER |b 4052889959 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 08-02-22 | ||
981 | |2 2403 |1 01 |x DE-LFER |r https://doi.org/10.1002/ajh.25825 | ||
981 | |2 2403 |1 01 |x DE-LFER |r https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2020 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_21 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_10 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1477558896 |a Schwaab, Juliana | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416468528 |a III. Medizinische Klinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_1 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1562793470 |a Naumann, Nicole | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416468528 |a III. Medizinische Klinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_2 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s p |0 (DE-627)1668484099 |a Lübke, Johannes | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s k |0 (DE-627)1416468528 |a III. Medizinische Klinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |a pos_3 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s p |0 (DE-627)1482083817 |a Jawhar, Mohamad | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s k |0 (DE-627)1416468528 |a III. Medizinische Klinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |a pos_4 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s p |0 (DE-627)1460939530 |a Fabarius, Alice | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s k |0 (DE-627)1416468528 |a III. Medizinische Klinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |a pos_14 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s p |0 (DE-627)1448669421 |a Hofmann, Wolf-Karsten | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s k |0 (DE-627)1416468528 |a III. Medizinische Klinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |a pos_17 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s p |0 (DE-627)1446321282 |a Reiter, Andreas | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s k |0 (DE-627)1416468528 |a III. Medizinische Klinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s s |a pos_20 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 11 |s p |0 (DE-627)1477558845 |a Metzgeroth, Georgia | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 11 |s k |0 (DE-627)1416468528 |a III. Medizinische Klinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 11 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 11 |s s |a pos_21 |
author_variant |
j s js n n nn j l jl m j mj t c s tc tcs m s w ms msw r f rf p j j pj pjj f s l fs fsl r p l rp rpl n s ns t h th h p h hph a f af c h ch a b ab w k h wkh n c c nc ncc a h ah a r ar g m gm |
---|---|
matchkey_str |
article:10968652:2020----::epneoyoieiaeniiosnylinolsssoitdihc1a2 |
oclc_num |
1295679705 |
hierarchy_sort_str |
2020 |
publishDate |
2020 |
allfields |
10.1002/ajh.25825 doi (DE-627)1786601257 (DE-599)KXP1786601257 (OCoLC)1295679705 DE-627 ger DE-627 rda eng Schwaab, Juliana 1982- verfasserin (DE-588)1051912687 (DE-627)787019399 (DE-576)407558764 aut Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes Juliana Schwaab, Nicole Naumann, Johannes Luebke, Mohamad Jawhar, Tim C.P. Somervaille, Mark S. Williams, Rebecca Frewin, Philipp J. Jost, Felix S. Lichtenegger, Paul La Rosée, Nicola Storch, Torsten Haferlach, Hans-Peter Horny, Alice Fabarius, Claudia Haferlach, Andreas Burchert, Wolf-Karsten Hofmann, Nicholas C.P. Cross, Andreas Hochhaus, Andreas Reiter, Georgia Metzgeroth 2020 10 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier 12 April 2020 First published: 12 April 2020 We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n = 8; BCR-JAK2, n = 1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n = 9). On ruxolitinib (median 24 months, range 2-36 months), a complete hematologic response (CHR) and complete cytogenetic response (CCR) was achieved by five of nine and two of nine patients, respectively. However, ruxolitinib was stopped in eight of nine patients because of primary resistance (n = 3), progression (n = 3) or planned allogeneic stem cell transplantation (allo SCT, n = 2). At a median of 36 months (range 4-78 months) from diagnosis, five of nine patients are alive: four of six patients after allo SCT and one patient who remains on ruxolitinib. In ETV6-ABL1 positive patients, a durable CHR was achieved by four of nine patients (imatinib with one of five, nilotinib with two of three, dasatinib with one of one). Because of inadequate efficacy (lack of hematological and/or cytogenetic/molecular response), six of nine patients (imatinib, n = 5; nilotinib, n = 1) were switched to nilotinib or dasatinib. At a median of 23 months (range 3-60 months) from diagnosis, five of nine patients are in CCR or complete molecular response (nilotinib, n = 2; dasatinib, n = 2; allo SCT, n = 1) while two of nine patients have died. We conclude that (a) responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and (b) nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6-ABL1 positive patients. Naumann, Nicole 1988- verfasserin (DE-588)1138951838 (DE-627)896569624 (DE-576)49279314X aut Lübke, Johannes 1996- verfasserin (DE-588)1189769867 (DE-627)1668483645 aut Jawhar, Mohamad 1986- verfasserin (DE-588)1046172905 (DE-627)775847747 (DE-576)399437061 aut Somervaille, Tim C.P. verfasserin aut Williams, Mark S. verfasserin aut Frewin, Rebecca verfasserin aut Jost, Philipp J. verfasserin aut Lichtenegger, Felix S. verfasserin aut La Rosée, Paul verfasserin aut Storch, Nicola verfasserin aut Haferlach, Torsten verfasserin aut Horny, Hans-Peter verfasserin aut Fabarius, Alice 1965- verfasserin (DE-588)1037001281 (DE-627)751728314 (DE-576)390896667 aut Haferlach, Claudia verfasserin aut Burchert, Andreas verfasserin aut Hofmann, Wolf-Karsten 1967- verfasserin (DE-588)114154635 (DE-627)691208751 (DE-576)351568336 aut Cross, Nicholas C.P. verfasserin aut Hochhaus, Andreas verfasserin aut Reiter, Andreas 1964- verfasserin (DE-588)172629551 (DE-627)697563766 (DE-576)133488594 aut Metzgeroth, Georgia 1972- verfasserin (DE-588)1051897661 (DE-627)786986832 (DE-576)407534075 aut Enthalten in American journal of hematology New York, NY : Wiley-Liss, 1976 95(2020), 7 vom: Apr., Seite 824-833 Online-Ressource (DE-627)302923349 (DE-600)1492749-4 (DE-576)094060002 1096-8652 nnns volume:95 year:2020 number:7 month:04 pages:824-833 extent:10 https://doi.org/10.1002/ajh.25825 Verlag Resolving-System kostenfrei Volltext https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825 Verlag kostenfrei Volltext GBV_USEFLAG_U GBV_ILN_2011 ISIL_DE-16 SYSFLAG_1 GBV_KXP GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_266 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_647 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 GBV_ILN_2013 GBV_ILN_2403 GBV_ILN_2013 ISIL_DE-16-250 GBV_ILN_2403 ISIL_DE-LFER AR 95 2020 7 4 824-833 10 2011 01 DE-16 4039864360 00 --%%-- --%%-- --%%-- --%%-- l01 20-01-22 2013 01 DE-16-250 4045645756 00 --%%-- --%%-- --%%-- --%%-- l01 27-01-22 2403 01 DE-LFER 4052889959 00 --%%-- --%%-- n --%%-- l01 08-02-22 2403 01 DE-LFER https://doi.org/10.1002/ajh.25825 2403 01 DE-LFER https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825 2013 01 DE-16-250 00 s hd2020 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_21 2013 01 DE-16-250 03 s s_10 2013 01 DE-16-250 04 p (DE-627)1477558896 Schwaab, Juliana 2013 01 DE-16-250 04 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_1 2013 01 DE-16-250 05 p (DE-627)1562793470 Naumann, Nicole 2013 01 DE-16-250 05 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 05 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 05 s pos_2 2013 01 DE-16-250 06 p (DE-627)1668484099 Lübke, Johannes 2013 01 DE-16-250 06 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 06 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 06 s pos_3 2013 01 DE-16-250 07 p (DE-627)1482083817 Jawhar, Mohamad 2013 01 DE-16-250 07 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 07 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 07 s pos_4 2013 01 DE-16-250 08 p (DE-627)1460939530 Fabarius, Alice 2013 01 DE-16-250 08 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 08 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 08 s pos_14 2013 01 DE-16-250 09 p (DE-627)1448669421 Hofmann, Wolf-Karsten 2013 01 DE-16-250 09 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 09 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 09 s pos_17 2013 01 DE-16-250 10 p (DE-627)1446321282 Reiter, Andreas 2013 01 DE-16-250 10 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 10 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 10 s pos_20 2013 01 DE-16-250 11 p (DE-627)1477558845 Metzgeroth, Georgia 2013 01 DE-16-250 11 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 11 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 11 s pos_21 |
spelling |
10.1002/ajh.25825 doi (DE-627)1786601257 (DE-599)KXP1786601257 (OCoLC)1295679705 DE-627 ger DE-627 rda eng Schwaab, Juliana 1982- verfasserin (DE-588)1051912687 (DE-627)787019399 (DE-576)407558764 aut Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes Juliana Schwaab, Nicole Naumann, Johannes Luebke, Mohamad Jawhar, Tim C.P. Somervaille, Mark S. Williams, Rebecca Frewin, Philipp J. Jost, Felix S. Lichtenegger, Paul La Rosée, Nicola Storch, Torsten Haferlach, Hans-Peter Horny, Alice Fabarius, Claudia Haferlach, Andreas Burchert, Wolf-Karsten Hofmann, Nicholas C.P. Cross, Andreas Hochhaus, Andreas Reiter, Georgia Metzgeroth 2020 10 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier 12 April 2020 First published: 12 April 2020 We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n = 8; BCR-JAK2, n = 1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n = 9). On ruxolitinib (median 24 months, range 2-36 months), a complete hematologic response (CHR) and complete cytogenetic response (CCR) was achieved by five of nine and two of nine patients, respectively. However, ruxolitinib was stopped in eight of nine patients because of primary resistance (n = 3), progression (n = 3) or planned allogeneic stem cell transplantation (allo SCT, n = 2). At a median of 36 months (range 4-78 months) from diagnosis, five of nine patients are alive: four of six patients after allo SCT and one patient who remains on ruxolitinib. In ETV6-ABL1 positive patients, a durable CHR was achieved by four of nine patients (imatinib with one of five, nilotinib with two of three, dasatinib with one of one). Because of inadequate efficacy (lack of hematological and/or cytogenetic/molecular response), six of nine patients (imatinib, n = 5; nilotinib, n = 1) were switched to nilotinib or dasatinib. At a median of 23 months (range 3-60 months) from diagnosis, five of nine patients are in CCR or complete molecular response (nilotinib, n = 2; dasatinib, n = 2; allo SCT, n = 1) while two of nine patients have died. We conclude that (a) responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and (b) nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6-ABL1 positive patients. Naumann, Nicole 1988- verfasserin (DE-588)1138951838 (DE-627)896569624 (DE-576)49279314X aut Lübke, Johannes 1996- verfasserin (DE-588)1189769867 (DE-627)1668483645 aut Jawhar, Mohamad 1986- verfasserin (DE-588)1046172905 (DE-627)775847747 (DE-576)399437061 aut Somervaille, Tim C.P. verfasserin aut Williams, Mark S. verfasserin aut Frewin, Rebecca verfasserin aut Jost, Philipp J. verfasserin aut Lichtenegger, Felix S. verfasserin aut La Rosée, Paul verfasserin aut Storch, Nicola verfasserin aut Haferlach, Torsten verfasserin aut Horny, Hans-Peter verfasserin aut Fabarius, Alice 1965- verfasserin (DE-588)1037001281 (DE-627)751728314 (DE-576)390896667 aut Haferlach, Claudia verfasserin aut Burchert, Andreas verfasserin aut Hofmann, Wolf-Karsten 1967- verfasserin (DE-588)114154635 (DE-627)691208751 (DE-576)351568336 aut Cross, Nicholas C.P. verfasserin aut Hochhaus, Andreas verfasserin aut Reiter, Andreas 1964- verfasserin (DE-588)172629551 (DE-627)697563766 (DE-576)133488594 aut Metzgeroth, Georgia 1972- verfasserin (DE-588)1051897661 (DE-627)786986832 (DE-576)407534075 aut Enthalten in American journal of hematology New York, NY : Wiley-Liss, 1976 95(2020), 7 vom: Apr., Seite 824-833 Online-Ressource (DE-627)302923349 (DE-600)1492749-4 (DE-576)094060002 1096-8652 nnns volume:95 year:2020 number:7 month:04 pages:824-833 extent:10 https://doi.org/10.1002/ajh.25825 Verlag Resolving-System kostenfrei Volltext https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825 Verlag kostenfrei Volltext GBV_USEFLAG_U GBV_ILN_2011 ISIL_DE-16 SYSFLAG_1 GBV_KXP GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_266 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_647 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 GBV_ILN_2013 GBV_ILN_2403 GBV_ILN_2013 ISIL_DE-16-250 GBV_ILN_2403 ISIL_DE-LFER AR 95 2020 7 4 824-833 10 2011 01 DE-16 4039864360 00 --%%-- --%%-- --%%-- --%%-- l01 20-01-22 2013 01 DE-16-250 4045645756 00 --%%-- --%%-- --%%-- --%%-- l01 27-01-22 2403 01 DE-LFER 4052889959 00 --%%-- --%%-- n --%%-- l01 08-02-22 2403 01 DE-LFER https://doi.org/10.1002/ajh.25825 2403 01 DE-LFER https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825 2013 01 DE-16-250 00 s hd2020 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_21 2013 01 DE-16-250 03 s s_10 2013 01 DE-16-250 04 p (DE-627)1477558896 Schwaab, Juliana 2013 01 DE-16-250 04 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_1 2013 01 DE-16-250 05 p (DE-627)1562793470 Naumann, Nicole 2013 01 DE-16-250 05 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 05 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 05 s pos_2 2013 01 DE-16-250 06 p (DE-627)1668484099 Lübke, Johannes 2013 01 DE-16-250 06 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 06 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 06 s pos_3 2013 01 DE-16-250 07 p (DE-627)1482083817 Jawhar, Mohamad 2013 01 DE-16-250 07 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 07 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 07 s pos_4 2013 01 DE-16-250 08 p (DE-627)1460939530 Fabarius, Alice 2013 01 DE-16-250 08 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 08 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 08 s pos_14 2013 01 DE-16-250 09 p (DE-627)1448669421 Hofmann, Wolf-Karsten 2013 01 DE-16-250 09 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 09 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 09 s pos_17 2013 01 DE-16-250 10 p (DE-627)1446321282 Reiter, Andreas 2013 01 DE-16-250 10 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 10 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 10 s pos_20 2013 01 DE-16-250 11 p (DE-627)1477558845 Metzgeroth, Georgia 2013 01 DE-16-250 11 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 11 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 11 s pos_21 |
allfields_unstemmed |
10.1002/ajh.25825 doi (DE-627)1786601257 (DE-599)KXP1786601257 (OCoLC)1295679705 DE-627 ger DE-627 rda eng Schwaab, Juliana 1982- verfasserin (DE-588)1051912687 (DE-627)787019399 (DE-576)407558764 aut Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes Juliana Schwaab, Nicole Naumann, Johannes Luebke, Mohamad Jawhar, Tim C.P. Somervaille, Mark S. Williams, Rebecca Frewin, Philipp J. Jost, Felix S. Lichtenegger, Paul La Rosée, Nicola Storch, Torsten Haferlach, Hans-Peter Horny, Alice Fabarius, Claudia Haferlach, Andreas Burchert, Wolf-Karsten Hofmann, Nicholas C.P. Cross, Andreas Hochhaus, Andreas Reiter, Georgia Metzgeroth 2020 10 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier 12 April 2020 First published: 12 April 2020 We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n = 8; BCR-JAK2, n = 1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n = 9). On ruxolitinib (median 24 months, range 2-36 months), a complete hematologic response (CHR) and complete cytogenetic response (CCR) was achieved by five of nine and two of nine patients, respectively. However, ruxolitinib was stopped in eight of nine patients because of primary resistance (n = 3), progression (n = 3) or planned allogeneic stem cell transplantation (allo SCT, n = 2). At a median of 36 months (range 4-78 months) from diagnosis, five of nine patients are alive: four of six patients after allo SCT and one patient who remains on ruxolitinib. In ETV6-ABL1 positive patients, a durable CHR was achieved by four of nine patients (imatinib with one of five, nilotinib with two of three, dasatinib with one of one). Because of inadequate efficacy (lack of hematological and/or cytogenetic/molecular response), six of nine patients (imatinib, n = 5; nilotinib, n = 1) were switched to nilotinib or dasatinib. At a median of 23 months (range 3-60 months) from diagnosis, five of nine patients are in CCR or complete molecular response (nilotinib, n = 2; dasatinib, n = 2; allo SCT, n = 1) while two of nine patients have died. We conclude that (a) responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and (b) nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6-ABL1 positive patients. Naumann, Nicole 1988- verfasserin (DE-588)1138951838 (DE-627)896569624 (DE-576)49279314X aut Lübke, Johannes 1996- verfasserin (DE-588)1189769867 (DE-627)1668483645 aut Jawhar, Mohamad 1986- verfasserin (DE-588)1046172905 (DE-627)775847747 (DE-576)399437061 aut Somervaille, Tim C.P. verfasserin aut Williams, Mark S. verfasserin aut Frewin, Rebecca verfasserin aut Jost, Philipp J. verfasserin aut Lichtenegger, Felix S. verfasserin aut La Rosée, Paul verfasserin aut Storch, Nicola verfasserin aut Haferlach, Torsten verfasserin aut Horny, Hans-Peter verfasserin aut Fabarius, Alice 1965- verfasserin (DE-588)1037001281 (DE-627)751728314 (DE-576)390896667 aut Haferlach, Claudia verfasserin aut Burchert, Andreas verfasserin aut Hofmann, Wolf-Karsten 1967- verfasserin (DE-588)114154635 (DE-627)691208751 (DE-576)351568336 aut Cross, Nicholas C.P. verfasserin aut Hochhaus, Andreas verfasserin aut Reiter, Andreas 1964- verfasserin (DE-588)172629551 (DE-627)697563766 (DE-576)133488594 aut Metzgeroth, Georgia 1972- verfasserin (DE-588)1051897661 (DE-627)786986832 (DE-576)407534075 aut Enthalten in American journal of hematology New York, NY : Wiley-Liss, 1976 95(2020), 7 vom: Apr., Seite 824-833 Online-Ressource (DE-627)302923349 (DE-600)1492749-4 (DE-576)094060002 1096-8652 nnns volume:95 year:2020 number:7 month:04 pages:824-833 extent:10 https://doi.org/10.1002/ajh.25825 Verlag Resolving-System kostenfrei Volltext https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825 Verlag kostenfrei Volltext GBV_USEFLAG_U GBV_ILN_2011 ISIL_DE-16 SYSFLAG_1 GBV_KXP GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_266 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_647 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 GBV_ILN_2013 GBV_ILN_2403 GBV_ILN_2013 ISIL_DE-16-250 GBV_ILN_2403 ISIL_DE-LFER AR 95 2020 7 4 824-833 10 2011 01 DE-16 4039864360 00 --%%-- --%%-- --%%-- --%%-- l01 20-01-22 2013 01 DE-16-250 4045645756 00 --%%-- --%%-- --%%-- --%%-- l01 27-01-22 2403 01 DE-LFER 4052889959 00 --%%-- --%%-- n --%%-- l01 08-02-22 2403 01 DE-LFER https://doi.org/10.1002/ajh.25825 2403 01 DE-LFER https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825 2013 01 DE-16-250 00 s hd2020 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_21 2013 01 DE-16-250 03 s s_10 2013 01 DE-16-250 04 p (DE-627)1477558896 Schwaab, Juliana 2013 01 DE-16-250 04 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_1 2013 01 DE-16-250 05 p (DE-627)1562793470 Naumann, Nicole 2013 01 DE-16-250 05 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 05 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 05 s pos_2 2013 01 DE-16-250 06 p (DE-627)1668484099 Lübke, Johannes 2013 01 DE-16-250 06 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 06 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 06 s pos_3 2013 01 DE-16-250 07 p (DE-627)1482083817 Jawhar, Mohamad 2013 01 DE-16-250 07 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 07 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 07 s pos_4 2013 01 DE-16-250 08 p (DE-627)1460939530 Fabarius, Alice 2013 01 DE-16-250 08 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 08 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 08 s pos_14 2013 01 DE-16-250 09 p (DE-627)1448669421 Hofmann, Wolf-Karsten 2013 01 DE-16-250 09 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 09 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 09 s pos_17 2013 01 DE-16-250 10 p (DE-627)1446321282 Reiter, Andreas 2013 01 DE-16-250 10 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 10 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 10 s pos_20 2013 01 DE-16-250 11 p (DE-627)1477558845 Metzgeroth, Georgia 2013 01 DE-16-250 11 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 11 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 11 s pos_21 |
allfieldsGer |
10.1002/ajh.25825 doi (DE-627)1786601257 (DE-599)KXP1786601257 (OCoLC)1295679705 DE-627 ger DE-627 rda eng Schwaab, Juliana 1982- verfasserin (DE-588)1051912687 (DE-627)787019399 (DE-576)407558764 aut Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes Juliana Schwaab, Nicole Naumann, Johannes Luebke, Mohamad Jawhar, Tim C.P. Somervaille, Mark S. Williams, Rebecca Frewin, Philipp J. Jost, Felix S. Lichtenegger, Paul La Rosée, Nicola Storch, Torsten Haferlach, Hans-Peter Horny, Alice Fabarius, Claudia Haferlach, Andreas Burchert, Wolf-Karsten Hofmann, Nicholas C.P. Cross, Andreas Hochhaus, Andreas Reiter, Georgia Metzgeroth 2020 10 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier 12 April 2020 First published: 12 April 2020 We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n = 8; BCR-JAK2, n = 1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n = 9). On ruxolitinib (median 24 months, range 2-36 months), a complete hematologic response (CHR) and complete cytogenetic response (CCR) was achieved by five of nine and two of nine patients, respectively. However, ruxolitinib was stopped in eight of nine patients because of primary resistance (n = 3), progression (n = 3) or planned allogeneic stem cell transplantation (allo SCT, n = 2). At a median of 36 months (range 4-78 months) from diagnosis, five of nine patients are alive: four of six patients after allo SCT and one patient who remains on ruxolitinib. In ETV6-ABL1 positive patients, a durable CHR was achieved by four of nine patients (imatinib with one of five, nilotinib with two of three, dasatinib with one of one). Because of inadequate efficacy (lack of hematological and/or cytogenetic/molecular response), six of nine patients (imatinib, n = 5; nilotinib, n = 1) were switched to nilotinib or dasatinib. At a median of 23 months (range 3-60 months) from diagnosis, five of nine patients are in CCR or complete molecular response (nilotinib, n = 2; dasatinib, n = 2; allo SCT, n = 1) while two of nine patients have died. We conclude that (a) responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and (b) nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6-ABL1 positive patients. Naumann, Nicole 1988- verfasserin (DE-588)1138951838 (DE-627)896569624 (DE-576)49279314X aut Lübke, Johannes 1996- verfasserin (DE-588)1189769867 (DE-627)1668483645 aut Jawhar, Mohamad 1986- verfasserin (DE-588)1046172905 (DE-627)775847747 (DE-576)399437061 aut Somervaille, Tim C.P. verfasserin aut Williams, Mark S. verfasserin aut Frewin, Rebecca verfasserin aut Jost, Philipp J. verfasserin aut Lichtenegger, Felix S. verfasserin aut La Rosée, Paul verfasserin aut Storch, Nicola verfasserin aut Haferlach, Torsten verfasserin aut Horny, Hans-Peter verfasserin aut Fabarius, Alice 1965- verfasserin (DE-588)1037001281 (DE-627)751728314 (DE-576)390896667 aut Haferlach, Claudia verfasserin aut Burchert, Andreas verfasserin aut Hofmann, Wolf-Karsten 1967- verfasserin (DE-588)114154635 (DE-627)691208751 (DE-576)351568336 aut Cross, Nicholas C.P. verfasserin aut Hochhaus, Andreas verfasserin aut Reiter, Andreas 1964- verfasserin (DE-588)172629551 (DE-627)697563766 (DE-576)133488594 aut Metzgeroth, Georgia 1972- verfasserin (DE-588)1051897661 (DE-627)786986832 (DE-576)407534075 aut Enthalten in American journal of hematology New York, NY : Wiley-Liss, 1976 95(2020), 7 vom: Apr., Seite 824-833 Online-Ressource (DE-627)302923349 (DE-600)1492749-4 (DE-576)094060002 1096-8652 nnns volume:95 year:2020 number:7 month:04 pages:824-833 extent:10 https://doi.org/10.1002/ajh.25825 Verlag Resolving-System kostenfrei Volltext https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825 Verlag kostenfrei Volltext GBV_USEFLAG_U GBV_ILN_2011 ISIL_DE-16 SYSFLAG_1 GBV_KXP GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_266 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_647 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 GBV_ILN_2013 GBV_ILN_2403 GBV_ILN_2013 ISIL_DE-16-250 GBV_ILN_2403 ISIL_DE-LFER AR 95 2020 7 4 824-833 10 2011 01 DE-16 4039864360 00 --%%-- --%%-- --%%-- --%%-- l01 20-01-22 2013 01 DE-16-250 4045645756 00 --%%-- --%%-- --%%-- --%%-- l01 27-01-22 2403 01 DE-LFER 4052889959 00 --%%-- --%%-- n --%%-- l01 08-02-22 2403 01 DE-LFER https://doi.org/10.1002/ajh.25825 2403 01 DE-LFER https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825 2013 01 DE-16-250 00 s hd2020 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_21 2013 01 DE-16-250 03 s s_10 2013 01 DE-16-250 04 p (DE-627)1477558896 Schwaab, Juliana 2013 01 DE-16-250 04 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_1 2013 01 DE-16-250 05 p (DE-627)1562793470 Naumann, Nicole 2013 01 DE-16-250 05 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 05 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 05 s pos_2 2013 01 DE-16-250 06 p (DE-627)1668484099 Lübke, Johannes 2013 01 DE-16-250 06 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 06 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 06 s pos_3 2013 01 DE-16-250 07 p (DE-627)1482083817 Jawhar, Mohamad 2013 01 DE-16-250 07 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 07 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 07 s pos_4 2013 01 DE-16-250 08 p (DE-627)1460939530 Fabarius, Alice 2013 01 DE-16-250 08 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 08 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 08 s pos_14 2013 01 DE-16-250 09 p (DE-627)1448669421 Hofmann, Wolf-Karsten 2013 01 DE-16-250 09 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 09 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 09 s pos_17 2013 01 DE-16-250 10 p (DE-627)1446321282 Reiter, Andreas 2013 01 DE-16-250 10 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 10 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 10 s pos_20 2013 01 DE-16-250 11 p (DE-627)1477558845 Metzgeroth, Georgia 2013 01 DE-16-250 11 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 11 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 11 s pos_21 |
allfieldsSound |
10.1002/ajh.25825 doi (DE-627)1786601257 (DE-599)KXP1786601257 (OCoLC)1295679705 DE-627 ger DE-627 rda eng Schwaab, Juliana 1982- verfasserin (DE-588)1051912687 (DE-627)787019399 (DE-576)407558764 aut Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes Juliana Schwaab, Nicole Naumann, Johannes Luebke, Mohamad Jawhar, Tim C.P. Somervaille, Mark S. Williams, Rebecca Frewin, Philipp J. Jost, Felix S. Lichtenegger, Paul La Rosée, Nicola Storch, Torsten Haferlach, Hans-Peter Horny, Alice Fabarius, Claudia Haferlach, Andreas Burchert, Wolf-Karsten Hofmann, Nicholas C.P. Cross, Andreas Hochhaus, Andreas Reiter, Georgia Metzgeroth 2020 10 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier 12 April 2020 First published: 12 April 2020 We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n = 8; BCR-JAK2, n = 1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n = 9). On ruxolitinib (median 24 months, range 2-36 months), a complete hematologic response (CHR) and complete cytogenetic response (CCR) was achieved by five of nine and two of nine patients, respectively. However, ruxolitinib was stopped in eight of nine patients because of primary resistance (n = 3), progression (n = 3) or planned allogeneic stem cell transplantation (allo SCT, n = 2). At a median of 36 months (range 4-78 months) from diagnosis, five of nine patients are alive: four of six patients after allo SCT and one patient who remains on ruxolitinib. In ETV6-ABL1 positive patients, a durable CHR was achieved by four of nine patients (imatinib with one of five, nilotinib with two of three, dasatinib with one of one). Because of inadequate efficacy (lack of hematological and/or cytogenetic/molecular response), six of nine patients (imatinib, n = 5; nilotinib, n = 1) were switched to nilotinib or dasatinib. At a median of 23 months (range 3-60 months) from diagnosis, five of nine patients are in CCR or complete molecular response (nilotinib, n = 2; dasatinib, n = 2; allo SCT, n = 1) while two of nine patients have died. We conclude that (a) responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and (b) nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6-ABL1 positive patients. Naumann, Nicole 1988- verfasserin (DE-588)1138951838 (DE-627)896569624 (DE-576)49279314X aut Lübke, Johannes 1996- verfasserin (DE-588)1189769867 (DE-627)1668483645 aut Jawhar, Mohamad 1986- verfasserin (DE-588)1046172905 (DE-627)775847747 (DE-576)399437061 aut Somervaille, Tim C.P. verfasserin aut Williams, Mark S. verfasserin aut Frewin, Rebecca verfasserin aut Jost, Philipp J. verfasserin aut Lichtenegger, Felix S. verfasserin aut La Rosée, Paul verfasserin aut Storch, Nicola verfasserin aut Haferlach, Torsten verfasserin aut Horny, Hans-Peter verfasserin aut Fabarius, Alice 1965- verfasserin (DE-588)1037001281 (DE-627)751728314 (DE-576)390896667 aut Haferlach, Claudia verfasserin aut Burchert, Andreas verfasserin aut Hofmann, Wolf-Karsten 1967- verfasserin (DE-588)114154635 (DE-627)691208751 (DE-576)351568336 aut Cross, Nicholas C.P. verfasserin aut Hochhaus, Andreas verfasserin aut Reiter, Andreas 1964- verfasserin (DE-588)172629551 (DE-627)697563766 (DE-576)133488594 aut Metzgeroth, Georgia 1972- verfasserin (DE-588)1051897661 (DE-627)786986832 (DE-576)407534075 aut Enthalten in American journal of hematology New York, NY : Wiley-Liss, 1976 95(2020), 7 vom: Apr., Seite 824-833 Online-Ressource (DE-627)302923349 (DE-600)1492749-4 (DE-576)094060002 1096-8652 nnns volume:95 year:2020 number:7 month:04 pages:824-833 extent:10 https://doi.org/10.1002/ajh.25825 Verlag Resolving-System kostenfrei Volltext https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825 Verlag kostenfrei Volltext GBV_USEFLAG_U GBV_ILN_2011 ISIL_DE-16 SYSFLAG_1 GBV_KXP GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_266 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_647 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 GBV_ILN_2013 GBV_ILN_2403 GBV_ILN_2013 ISIL_DE-16-250 GBV_ILN_2403 ISIL_DE-LFER AR 95 2020 7 4 824-833 10 2011 01 DE-16 4039864360 00 --%%-- --%%-- --%%-- --%%-- l01 20-01-22 2013 01 DE-16-250 4045645756 00 --%%-- --%%-- --%%-- --%%-- l01 27-01-22 2403 01 DE-LFER 4052889959 00 --%%-- --%%-- n --%%-- l01 08-02-22 2403 01 DE-LFER https://doi.org/10.1002/ajh.25825 2403 01 DE-LFER https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825 2013 01 DE-16-250 00 s hd2020 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_21 2013 01 DE-16-250 03 s s_10 2013 01 DE-16-250 04 p (DE-627)1477558896 Schwaab, Juliana 2013 01 DE-16-250 04 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_1 2013 01 DE-16-250 05 p (DE-627)1562793470 Naumann, Nicole 2013 01 DE-16-250 05 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 05 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 05 s pos_2 2013 01 DE-16-250 06 p (DE-627)1668484099 Lübke, Johannes 2013 01 DE-16-250 06 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 06 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 06 s pos_3 2013 01 DE-16-250 07 p (DE-627)1482083817 Jawhar, Mohamad 2013 01 DE-16-250 07 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 07 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 07 s pos_4 2013 01 DE-16-250 08 p (DE-627)1460939530 Fabarius, Alice 2013 01 DE-16-250 08 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 08 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 08 s pos_14 2013 01 DE-16-250 09 p (DE-627)1448669421 Hofmann, Wolf-Karsten 2013 01 DE-16-250 09 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 09 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 09 s pos_17 2013 01 DE-16-250 10 p (DE-627)1446321282 Reiter, Andreas 2013 01 DE-16-250 10 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 10 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 10 s pos_20 2013 01 DE-16-250 11 p (DE-627)1477558845 Metzgeroth, Georgia 2013 01 DE-16-250 11 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 11 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 11 s pos_21 |
language |
English |
source |
Enthalten in American journal of hematology 95(2020), 7 vom: Apr., Seite 824-833 volume:95 year:2020 number:7 month:04 pages:824-833 extent:10 |
sourceStr |
Enthalten in American journal of hematology 95(2020), 7 vom: Apr., Seite 824-833 volume:95 year:2020 number:7 month:04 pages:824-833 extent:10 |
format_phy_str_mv |
Article |
building |
2011:0 2013:0 2403:0 |
institution |
findex.gbv.de |
selectbib_iln_str_mv |
2011@01 2013@01 2403@01 |
sw_local_iln_str_mv |
2013:hd2020 DE-16-250:hd2020 2013:wissenschaftlicher Artikel (Zeitschrift) DE-16-250:wissenschaftlicher Artikel (Zeitschrift) 2013:per_21 DE-16-250:per_21 2013:s_10 DE-16-250:s_10 2013:Schwaab, Juliana DE-16-250:Schwaab, Juliana 2013:III. Medizinische Klinik DE-16-250:III. Medizinische Klinik 2013:Verfasser DE-16-250:Verfasser 2013:pos_1 DE-16-250:pos_1 2013:Naumann, Nicole DE-16-250:Naumann, Nicole 2013:pos_2 DE-16-250:pos_2 2013:Lübke, Johannes DE-16-250:Lübke, Johannes 2013:pos_3 DE-16-250:pos_3 2013:Jawhar, Mohamad DE-16-250:Jawhar, Mohamad 2013:pos_4 DE-16-250:pos_4 2013:Fabarius, Alice DE-16-250:Fabarius, Alice 2013:pos_14 DE-16-250:pos_14 2013:Hofmann, Wolf-Karsten DE-16-250:Hofmann, Wolf-Karsten 2013:pos_17 DE-16-250:pos_17 2013:Reiter, Andreas DE-16-250:Reiter, Andreas 2013:pos_20 DE-16-250:pos_20 2013:Metzgeroth, Georgia DE-16-250:Metzgeroth, Georgia 2013:pos_21 DE-16-250:pos_21 |
isfreeaccess_bool |
true |
container_title |
American journal of hematology |
authorswithroles_txt_mv |
Schwaab, Juliana @@aut@@ Naumann, Nicole @@aut@@ Lübke, Johannes @@aut@@ Jawhar, Mohamad @@aut@@ Somervaille, Tim C.P. @@aut@@ Williams, Mark S. @@aut@@ Frewin, Rebecca @@aut@@ Jost, Philipp J. @@aut@@ Lichtenegger, Felix S. @@aut@@ La Rosée, Paul @@aut@@ Storch, Nicola @@aut@@ Haferlach, Torsten @@aut@@ Horny, Hans-Peter @@aut@@ Fabarius, Alice @@aut@@ Haferlach, Claudia @@aut@@ Burchert, Andreas @@aut@@ Hofmann, Wolf-Karsten @@aut@@ Cross, Nicholas C.P. @@aut@@ Hochhaus, Andreas @@aut@@ Reiter, Andreas @@aut@@ Metzgeroth, Georgia @@aut@@ |
publishDateDaySort_date |
2020-04-01T00:00:00Z |
hierarchy_top_id |
302923349 |
id |
1786601257 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">1786601257</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230105143119.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220120s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/ajh.25825</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)1786601257</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KXP1786601257</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1295679705</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schwaab, Juliana</subfield><subfield code="d">1982-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1051912687</subfield><subfield code="0">(DE-627)787019399</subfield><subfield code="0">(DE-576)407558764</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes</subfield><subfield code="c">Juliana Schwaab, Nicole Naumann, Johannes Luebke, Mohamad Jawhar, Tim C.P. Somervaille, Mark S. Williams, Rebecca Frewin, Philipp J. Jost, Felix S. Lichtenegger, Paul La Rosée, Nicola Storch, Torsten Haferlach, Hans-Peter Horny, Alice Fabarius, Claudia Haferlach, Andreas Burchert, Wolf-Karsten Hofmann, Nicholas C.P. Cross, Andreas Hochhaus, Andreas Reiter, Georgia Metzgeroth</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">12 April 2020</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">First published: 12 April 2020</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n = 8; BCR-JAK2, n = 1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n = 9). On ruxolitinib (median 24 months, range 2-36 months), a complete hematologic response (CHR) and complete cytogenetic response (CCR) was achieved by five of nine and two of nine patients, respectively. However, ruxolitinib was stopped in eight of nine patients because of primary resistance (n = 3), progression (n = 3) or planned allogeneic stem cell transplantation (allo SCT, n = 2). At a median of 36 months (range 4-78 months) from diagnosis, five of nine patients are alive: four of six patients after allo SCT and one patient who remains on ruxolitinib. In ETV6-ABL1 positive patients, a durable CHR was achieved by four of nine patients (imatinib with one of five, nilotinib with two of three, dasatinib with one of one). Because of inadequate efficacy (lack of hematological and/or cytogenetic/molecular response), six of nine patients (imatinib, n = 5; nilotinib, n = 1) were switched to nilotinib or dasatinib. At a median of 23 months (range 3-60 months) from diagnosis, five of nine patients are in CCR or complete molecular response (nilotinib, n = 2; dasatinib, n = 2; allo SCT, n = 1) while two of nine patients have died. We conclude that (a) responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and (b) nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6-ABL1 positive patients.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Naumann, Nicole</subfield><subfield code="d">1988-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1138951838</subfield><subfield code="0">(DE-627)896569624</subfield><subfield code="0">(DE-576)49279314X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lübke, Johannes</subfield><subfield code="d">1996-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1189769867</subfield><subfield code="0">(DE-627)1668483645</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jawhar, Mohamad</subfield><subfield code="d">1986-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1046172905</subfield><subfield code="0">(DE-627)775847747</subfield><subfield code="0">(DE-576)399437061</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Somervaille, Tim C.P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Williams, Mark S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Frewin, Rebecca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jost, Philipp J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lichtenegger, Felix S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">La Rosée, Paul</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Storch, Nicola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haferlach, Torsten</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Horny, Hans-Peter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fabarius, Alice</subfield><subfield code="d">1965-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1037001281</subfield><subfield code="0">(DE-627)751728314</subfield><subfield code="0">(DE-576)390896667</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haferlach, Claudia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Burchert, Andreas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hofmann, Wolf-Karsten</subfield><subfield code="d">1967-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)114154635</subfield><subfield code="0">(DE-627)691208751</subfield><subfield code="0">(DE-576)351568336</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cross, Nicholas C.P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hochhaus, Andreas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reiter, Andreas</subfield><subfield code="d">1964-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)172629551</subfield><subfield code="0">(DE-627)697563766</subfield><subfield code="0">(DE-576)133488594</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Metzgeroth, Georgia</subfield><subfield code="d">1972-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1051897661</subfield><subfield code="0">(DE-627)786986832</subfield><subfield code="0">(DE-576)407534075</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">American journal of hematology</subfield><subfield code="d">New York, NY : Wiley-Liss, 1976</subfield><subfield code="g">95(2020), 7 vom: Apr., Seite 824-833</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)302923349</subfield><subfield code="w">(DE-600)1492749-4</subfield><subfield code="w">(DE-576)094060002</subfield><subfield code="x">1096-8652</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:95</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:7</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:824-833</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/ajh.25825</subfield><subfield code="x">Verlag</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ISIL_DE-16</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_1</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_KXP</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_266</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_647</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2013</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2403</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2013</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ISIL_DE-16-250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2403</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ISIL_DE-LFER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">95</subfield><subfield code="j">2020</subfield><subfield code="e">7</subfield><subfield code="c">4</subfield><subfield code="h">824-833</subfield><subfield code="g">10</subfield></datafield><datafield tag="980" ind1=" " ind2=" "><subfield code="2">2011</subfield><subfield code="1">01</subfield><subfield code="x">DE-16</subfield><subfield code="b">4039864360</subfield><subfield code="c">00</subfield><subfield code="f">--%%--</subfield><subfield code="d">--%%--</subfield><subfield code="e">--%%--</subfield><subfield code="j">--%%--</subfield><subfield code="y">l01</subfield><subfield code="z">20-01-22</subfield></datafield><datafield tag="980" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="b">4045645756</subfield><subfield code="c">00</subfield><subfield code="f">--%%--</subfield><subfield code="d">--%%--</subfield><subfield code="e">--%%--</subfield><subfield code="j">--%%--</subfield><subfield code="y">l01</subfield><subfield code="z">27-01-22</subfield></datafield><datafield tag="980" ind1=" " ind2=" "><subfield code="2">2403</subfield><subfield code="1">01</subfield><subfield code="x">DE-LFER</subfield><subfield code="b">4052889959</subfield><subfield code="c">00</subfield><subfield code="f">--%%--</subfield><subfield code="d">--%%--</subfield><subfield code="e">n</subfield><subfield code="j">--%%--</subfield><subfield code="y">l01</subfield><subfield code="z">08-02-22</subfield></datafield><datafield tag="981" ind1=" " ind2=" "><subfield code="2">2403</subfield><subfield code="1">01</subfield><subfield code="x">DE-LFER</subfield><subfield code="r">https://doi.org/10.1002/ajh.25825</subfield></datafield><datafield tag="981" ind1=" " ind2=" "><subfield code="2">2403</subfield><subfield code="1">01</subfield><subfield code="x">DE-LFER</subfield><subfield code="r">https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">00</subfield><subfield code="s">s</subfield><subfield code="a">hd2020</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">01</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410508463</subfield><subfield code="a">wissenschaftlicher Artikel (Zeitschrift)</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">02</subfield><subfield code="s">s</subfield><subfield code="a">per_21</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">03</subfield><subfield code="s">s</subfield><subfield code="a">s_10</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1477558896</subfield><subfield code="a">Schwaab, Juliana</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="a">pos_1</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">05</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1562793470</subfield><subfield code="a">Naumann, Nicole</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">05</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">05</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">05</subfield><subfield code="s">s</subfield><subfield code="a">pos_2</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">06</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1668484099</subfield><subfield code="a">Lübke, Johannes</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">06</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">06</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">06</subfield><subfield code="s">s</subfield><subfield code="a">pos_3</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">07</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1482083817</subfield><subfield code="a">Jawhar, Mohamad</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">07</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">07</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">07</subfield><subfield code="s">s</subfield><subfield code="a">pos_4</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">08</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1460939530</subfield><subfield code="a">Fabarius, Alice</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">08</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">08</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">08</subfield><subfield code="s">s</subfield><subfield code="a">pos_14</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">09</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1448669421</subfield><subfield code="a">Hofmann, Wolf-Karsten</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">09</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">09</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">09</subfield><subfield code="s">s</subfield><subfield code="a">pos_17</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">10</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1446321282</subfield><subfield code="a">Reiter, Andreas</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">10</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">10</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">10</subfield><subfield code="s">s</subfield><subfield code="a">pos_20</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">11</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1477558845</subfield><subfield code="a">Metzgeroth, Georgia</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">11</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">11</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">11</subfield><subfield code="s">s</subfield><subfield code="a">pos_21</subfield></datafield></record></collection>
|
standort_str_mv |
--%%-- |
standort_iln_str_mv |
2011:--%%-- DE-16:--%%-- 2013:--%%-- DE-16-250:--%%-- 2403:--%%-- DE-LFER:--%%-- |
author |
Schwaab, Juliana 1982- |
spellingShingle |
Schwaab, Juliana 1982- 2013 hd2020 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_21 2013 s_10 2013 Schwaab, Juliana 2013 III. Medizinische Klinik 2013 Verfasser 2013 pos_1 2013 Naumann, Nicole 2013 pos_2 2013 Lübke, Johannes 2013 pos_3 2013 Jawhar, Mohamad 2013 pos_4 2013 Fabarius, Alice 2013 pos_14 2013 Hofmann, Wolf-Karsten 2013 pos_17 2013 Reiter, Andreas 2013 pos_20 2013 Metzgeroth, Georgia 2013 pos_21 Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes |
authorStr |
Schwaab, Juliana 1982- |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)302923349 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
typewithnormlink_str_mv |
Person@(DE-588)1051912687 DifferentiatedPerson@(DE-588)1051912687 DifferentiatedPerson@(DE-588)1138951838 Person@(DE-588)1138951838 DifferentiatedPerson@(DE-588)1189769867 Person@(DE-588)1189769867 DifferentiatedPerson@(DE-588)1046172905 Person@(DE-588)1046172905 Person@(DE-588)1037001281 DifferentiatedPerson@(DE-588)1037001281 DifferentiatedPerson@(DE-588)114154635 Person@(DE-588)114154635 DifferentiatedPerson@(DE-588)172629551 Person@(DE-588)172629551 Person@(DE-588)1051897661 DifferentiatedPerson@(DE-588)1051897661 |
collection |
KXP SWB GVK |
remote_str |
true |
last_changed_iln_str_mv |
2011@20-01-22 2013@27-01-22 2403@08-02-22 |
illustrated |
Not Illustrated |
issn |
1096-8652 |
topic_title |
2013 01 DE-16-250 00 s hd2020 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_21 2013 01 DE-16-250 03 s s_10 2013 01 DE-16-250 04 p (DE-627)1477558896 Schwaab, Juliana 2013 01 DE-16-250 04 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_1 2013 01 DE-16-250 05 p (DE-627)1562793470 Naumann, Nicole 2013 01 DE-16-250 05 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 05 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 05 s pos_2 2013 01 DE-16-250 06 p (DE-627)1668484099 Lübke, Johannes 2013 01 DE-16-250 06 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 06 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 06 s pos_3 2013 01 DE-16-250 07 p (DE-627)1482083817 Jawhar, Mohamad 2013 01 DE-16-250 07 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 07 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 07 s pos_4 2013 01 DE-16-250 08 p (DE-627)1460939530 Fabarius, Alice 2013 01 DE-16-250 08 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 08 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 08 s pos_14 2013 01 DE-16-250 09 p (DE-627)1448669421 Hofmann, Wolf-Karsten 2013 01 DE-16-250 09 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 09 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 09 s pos_17 2013 01 DE-16-250 10 p (DE-627)1446321282 Reiter, Andreas 2013 01 DE-16-250 10 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 10 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 10 s pos_20 2013 01 DE-16-250 11 p (DE-627)1477558845 Metzgeroth, Georgia 2013 01 DE-16-250 11 k (DE-627)1416468528 III. Medizinische Klinik 2013 01 DE-16-250 11 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 11 s pos_21 Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes Juliana Schwaab, Nicole Naumann, Johannes Luebke, Mohamad Jawhar, Tim C.P. Somervaille, Mark S. Williams, Rebecca Frewin, Philipp J. Jost, Felix S. Lichtenegger, Paul La Rosée, Nicola Storch, Torsten Haferlach, Hans-Peter Horny, Alice Fabarius, Claudia Haferlach, Andreas Burchert, Wolf-Karsten Hofmann, Nicholas C.P. Cross, Andreas Hochhaus, Andreas Reiter, Georgia Metzgeroth |
topic |
2013 hd2020 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_21 2013 s_10 2013 Schwaab, Juliana 2013 III. Medizinische Klinik 2013 Verfasser 2013 pos_1 2013 Naumann, Nicole 2013 pos_2 2013 Lübke, Johannes 2013 pos_3 2013 Jawhar, Mohamad 2013 pos_4 2013 Fabarius, Alice 2013 pos_14 2013 Hofmann, Wolf-Karsten 2013 pos_17 2013 Reiter, Andreas 2013 pos_20 2013 Metzgeroth, Georgia 2013 pos_21 |
topic_unstemmed |
2013 hd2020 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_21 2013 s_10 2013 Schwaab, Juliana 2013 III. Medizinische Klinik 2013 Verfasser 2013 pos_1 2013 Naumann, Nicole 2013 pos_2 2013 Lübke, Johannes 2013 pos_3 2013 Jawhar, Mohamad 2013 pos_4 2013 Fabarius, Alice 2013 pos_14 2013 Hofmann, Wolf-Karsten 2013 pos_17 2013 Reiter, Andreas 2013 pos_20 2013 Metzgeroth, Georgia 2013 pos_21 |
topic_browse |
2013 hd2020 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_21 2013 s_10 2013 Schwaab, Juliana 2013 III. Medizinische Klinik 2013 Verfasser 2013 pos_1 2013 Naumann, Nicole 2013 pos_2 2013 Lübke, Johannes 2013 pos_3 2013 Jawhar, Mohamad 2013 pos_4 2013 Fabarius, Alice 2013 pos_14 2013 Hofmann, Wolf-Karsten 2013 pos_17 2013 Reiter, Andreas 2013 pos_20 2013 Metzgeroth, Georgia 2013 pos_21 |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
standort_txtP_mv |
--%%-- |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
American journal of hematology |
normlinkwithtype_str_mv |
(DE-588)1051912687@Person (DE-588)1051912687@DifferentiatedPerson (DE-588)1138951838@DifferentiatedPerson (DE-588)1138951838@Person (DE-588)1189769867@DifferentiatedPerson (DE-588)1189769867@Person (DE-588)1046172905@DifferentiatedPerson (DE-588)1046172905@Person (DE-588)1037001281@Person (DE-588)1037001281@DifferentiatedPerson (DE-588)114154635@DifferentiatedPerson (DE-588)114154635@Person (DE-588)172629551@DifferentiatedPerson (DE-588)172629551@Person (DE-588)1051897661@Person (DE-588)1051897661@DifferentiatedPerson |
hierarchy_parent_id |
302923349 |
signature |
--%%-- |
signature_str_mv |
--%%-- |
hierarchy_top_title |
American journal of hematology |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)302923349 (DE-600)1492749-4 (DE-576)094060002 |
normlinkwithrole_str_mv |
(DE-588)1051912687@@aut@@ (DE-588)1138951838@@aut@@ (DE-588)1189769867@@aut@@ (DE-588)1046172905@@aut@@ (DE-588)1037001281@@aut@@ (DE-588)114154635@@aut@@ (DE-588)172629551@@aut@@ (DE-588)1051897661@@aut@@ |
title |
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes |
ctrlnum |
(DE-627)1786601257 (DE-599)KXP1786601257 (OCoLC)1295679705 |
title_full |
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes Juliana Schwaab, Nicole Naumann, Johannes Luebke, Mohamad Jawhar, Tim C.P. Somervaille, Mark S. Williams, Rebecca Frewin, Philipp J. Jost, Felix S. Lichtenegger, Paul La Rosée, Nicola Storch, Torsten Haferlach, Hans-Peter Horny, Alice Fabarius, Claudia Haferlach, Andreas Burchert, Wolf-Karsten Hofmann, Nicholas C.P. Cross, Andreas Hochhaus, Andreas Reiter, Georgia Metzgeroth |
author_sort |
Schwaab, Juliana 1982- |
journal |
American journal of hematology |
journalStr |
American journal of hematology |
callnumber-first-code |
- |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2020 |
contenttype_str_mv |
txt |
container_start_page |
824 |
author_browse |
Schwaab, Juliana Naumann, Nicole Lübke, Johannes Jawhar, Mohamad Somervaille, Tim C.P. Williams, Mark S. Frewin, Rebecca Jost, Philipp J. Lichtenegger, Felix S. La Rosée, Paul Storch, Nicola Haferlach, Torsten Horny, Hans-Peter Fabarius, Alice Haferlach, Claudia Burchert, Andreas Hofmann, Wolf-Karsten Cross, Nicholas C.P. Hochhaus, Andreas Reiter, Andreas Metzgeroth, Georgia |
selectkey |
2011:l 2013:l 2403:l |
container_volume |
95 |
physical |
10 |
format_se |
Elektronische Aufsätze |
author-letter |
Schwaab, Juliana |
doi_str_mv |
10.1002/ajh.25825 |
normlink |
1051912687 787019399 407558764 1138951838 896569624 49279314X 1189769867 1668483645 1046172905 775847747 399437061 1037001281 751728314 390896667 114154635 691208751 351568336 172629551 697563766 133488594 1051897661 786986832 407534075 1410508463 1477558896 1416468528 1410501914 1562793470 1668484099 1482083817 1460939530 1448669421 1446321282 1477558845 |
normlink_prefix_str_mv |
(DE-588)1051912687 (DE-627)787019399 (DE-576)407558764 (DE-588)1138951838 (DE-627)896569624 (DE-576)49279314X (DE-588)1189769867 (DE-627)1668483645 (DE-588)1046172905 (DE-627)775847747 (DE-576)399437061 (DE-588)1037001281 (DE-627)751728314 (DE-576)390896667 (DE-588)114154635 (DE-627)691208751 (DE-576)351568336 (DE-588)172629551 (DE-627)697563766 (DE-576)133488594 (DE-588)1051897661 (DE-627)786986832 (DE-576)407534075 (DE-627)1410508463 (DE-627)1477558896 (DE-627)1416468528 (DE-627)1410501914 (DE-627)1562793470 (DE-627)1668484099 (DE-627)1482083817 (DE-627)1460939530 (DE-627)1448669421 (DE-627)1446321282 (DE-627)1477558845 |
author2-role |
verfasserin |
title_sort |
response to tyrosine kinase inhibitors in myeloid neoplasms associated with pcm1-jak2, bcr-jak2 and etv6-abl1 fusion genes |
title_auth |
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes |
abstract |
We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n = 8; BCR-JAK2, n = 1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n = 9). On ruxolitinib (median 24 months, range 2-36 months), a complete hematologic response (CHR) and complete cytogenetic response (CCR) was achieved by five of nine and two of nine patients, respectively. However, ruxolitinib was stopped in eight of nine patients because of primary resistance (n = 3), progression (n = 3) or planned allogeneic stem cell transplantation (allo SCT, n = 2). At a median of 36 months (range 4-78 months) from diagnosis, five of nine patients are alive: four of six patients after allo SCT and one patient who remains on ruxolitinib. In ETV6-ABL1 positive patients, a durable CHR was achieved by four of nine patients (imatinib with one of five, nilotinib with two of three, dasatinib with one of one). Because of inadequate efficacy (lack of hematological and/or cytogenetic/molecular response), six of nine patients (imatinib, n = 5; nilotinib, n = 1) were switched to nilotinib or dasatinib. At a median of 23 months (range 3-60 months) from diagnosis, five of nine patients are in CCR or complete molecular response (nilotinib, n = 2; dasatinib, n = 2; allo SCT, n = 1) while two of nine patients have died. We conclude that (a) responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and (b) nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6-ABL1 positive patients. 12 April 2020 First published: 12 April 2020 |
abstractGer |
We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n = 8; BCR-JAK2, n = 1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n = 9). On ruxolitinib (median 24 months, range 2-36 months), a complete hematologic response (CHR) and complete cytogenetic response (CCR) was achieved by five of nine and two of nine patients, respectively. However, ruxolitinib was stopped in eight of nine patients because of primary resistance (n = 3), progression (n = 3) or planned allogeneic stem cell transplantation (allo SCT, n = 2). At a median of 36 months (range 4-78 months) from diagnosis, five of nine patients are alive: four of six patients after allo SCT and one patient who remains on ruxolitinib. In ETV6-ABL1 positive patients, a durable CHR was achieved by four of nine patients (imatinib with one of five, nilotinib with two of three, dasatinib with one of one). Because of inadequate efficacy (lack of hematological and/or cytogenetic/molecular response), six of nine patients (imatinib, n = 5; nilotinib, n = 1) were switched to nilotinib or dasatinib. At a median of 23 months (range 3-60 months) from diagnosis, five of nine patients are in CCR or complete molecular response (nilotinib, n = 2; dasatinib, n = 2; allo SCT, n = 1) while two of nine patients have died. We conclude that (a) responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and (b) nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6-ABL1 positive patients. 12 April 2020 First published: 12 April 2020 |
abstract_unstemmed |
We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n = 8; BCR-JAK2, n = 1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n = 9). On ruxolitinib (median 24 months, range 2-36 months), a complete hematologic response (CHR) and complete cytogenetic response (CCR) was achieved by five of nine and two of nine patients, respectively. However, ruxolitinib was stopped in eight of nine patients because of primary resistance (n = 3), progression (n = 3) or planned allogeneic stem cell transplantation (allo SCT, n = 2). At a median of 36 months (range 4-78 months) from diagnosis, five of nine patients are alive: four of six patients after allo SCT and one patient who remains on ruxolitinib. In ETV6-ABL1 positive patients, a durable CHR was achieved by four of nine patients (imatinib with one of five, nilotinib with two of three, dasatinib with one of one). Because of inadequate efficacy (lack of hematological and/or cytogenetic/molecular response), six of nine patients (imatinib, n = 5; nilotinib, n = 1) were switched to nilotinib or dasatinib. At a median of 23 months (range 3-60 months) from diagnosis, five of nine patients are in CCR or complete molecular response (nilotinib, n = 2; dasatinib, n = 2; allo SCT, n = 1) while two of nine patients have died. We conclude that (a) responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and (b) nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6-ABL1 positive patients. 12 April 2020 First published: 12 April 2020 |
collection_details |
GBV_USEFLAG_U GBV_ILN_2011 ISIL_DE-16 SYSFLAG_1 GBV_KXP GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_266 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_647 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 GBV_ILN_2013 GBV_ILN_2403 ISIL_DE-16-250 ISIL_DE-LFER |
container_issue |
7 |
title_short |
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes |
url |
https://doi.org/10.1002/ajh.25825 https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825 |
ausleihindikator_str_mv |
2011:- 2013:- 2403:n |
rolewithnormlink_str_mv |
@@aut@@(DE-588)1051912687 @@aut@@(DE-588)1138951838 @@aut@@(DE-588)1189769867 @@aut@@(DE-588)1046172905 @@aut@@(DE-588)1037001281 @@aut@@(DE-588)114154635 @@aut@@(DE-588)172629551 @@aut@@(DE-588)1051897661 |
remote_bool |
true |
author2 |
Naumann, Nicole 1988- Lübke, Johannes 1996- Jawhar, Mohamad 1986- Somervaille, Tim C.P. Williams, Mark S. Frewin, Rebecca Jost, Philipp J. Lichtenegger, Felix S. La Rosée, Paul Storch, Nicola Haferlach, Torsten Horny, Hans-Peter Fabarius, Alice 1965- Haferlach, Claudia Burchert, Andreas Hofmann, Wolf-Karsten 1967- Cross, Nicholas C.P. Hochhaus, Andreas Reiter, Andreas 1964- Metzgeroth, Georgia 1972- |
author2Str |
Naumann, Nicole 1988- Lübke, Johannes 1996- Jawhar, Mohamad 1986- Somervaille, Tim C.P. Williams, Mark S. Frewin, Rebecca Jost, Philipp J. Lichtenegger, Felix S. La Rosée, Paul Storch, Nicola Haferlach, Torsten Horny, Hans-Peter Fabarius, Alice 1965- Haferlach, Claudia Burchert, Andreas Hofmann, Wolf-Karsten 1967- Cross, Nicholas C.P. Hochhaus, Andreas Reiter, Andreas 1964- Metzgeroth, Georgia 1972- |
ppnlink |
302923349 |
GND_str_mv |
Schwaab, Juliana-Justina Schwaab, J. Schwaab, Juliane Schwaab, Juliana Naumann, Nicole Maria Naumann, N. Naumann, Nicole Luebke, Johannes Lübke, Johannes Jawhar, M. Jawhar, Mohamad Fabarius, Alice Charlotte Fabarius, A. Fabarius, Alice Hofmann, Wolf-K. Hofmann, W. K. Hofmann, W.-K. Hofmann, Wolf-Karsten Reiter, Andreas J. Reiter, A. Reiter, Andreas Johannes Reiter, Andreas Metzgeroth, Georgia Secunda Metzgeroth, G. Metzgeroth, Georgia |
GND_txt_mv |
Schwaab, Juliana-Justina Schwaab, J. Schwaab, Juliane Schwaab, Juliana Naumann, Nicole Maria Naumann, N. Naumann, Nicole Luebke, Johannes Lübke, Johannes Jawhar, M. Jawhar, Mohamad Fabarius, Alice Charlotte Fabarius, A. Fabarius, Alice Hofmann, Wolf-K. Hofmann, W. K. Hofmann, W.-K. Hofmann, Wolf-Karsten Reiter, Andreas J. Reiter, A. Reiter, Andreas Johannes Reiter, Andreas Metzgeroth, Georgia Secunda Metzgeroth, G. Metzgeroth, Georgia |
GND_txtF_mv |
Schwaab, Juliana-Justina Schwaab, J. Schwaab, Juliane Schwaab, Juliana Naumann, Nicole Maria Naumann, N. Naumann, Nicole Luebke, Johannes Lübke, Johannes Jawhar, M. Jawhar, Mohamad Fabarius, Alice Charlotte Fabarius, A. Fabarius, Alice Hofmann, Wolf-K. Hofmann, W. K. Hofmann, W.-K. Hofmann, Wolf-Karsten Reiter, Andreas J. Reiter, A. Reiter, Andreas Johannes Reiter, Andreas Metzgeroth, Georgia Secunda Metzgeroth, G. Metzgeroth, Georgia |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1002/ajh.25825 |
callnumber-a |
--%%-- |
up_date |
2024-07-04T23:14:19.009Z |
_version_ |
1803692129922318336 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">1786601257</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230105143119.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220120s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/ajh.25825</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)1786601257</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KXP1786601257</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1295679705</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schwaab, Juliana</subfield><subfield code="d">1982-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1051912687</subfield><subfield code="0">(DE-627)787019399</subfield><subfield code="0">(DE-576)407558764</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes</subfield><subfield code="c">Juliana Schwaab, Nicole Naumann, Johannes Luebke, Mohamad Jawhar, Tim C.P. Somervaille, Mark S. Williams, Rebecca Frewin, Philipp J. Jost, Felix S. Lichtenegger, Paul La Rosée, Nicola Storch, Torsten Haferlach, Hans-Peter Horny, Alice Fabarius, Claudia Haferlach, Andreas Burchert, Wolf-Karsten Hofmann, Nicholas C.P. Cross, Andreas Hochhaus, Andreas Reiter, Georgia Metzgeroth</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">12 April 2020</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">First published: 12 April 2020</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n = 8; BCR-JAK2, n = 1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n = 9). On ruxolitinib (median 24 months, range 2-36 months), a complete hematologic response (CHR) and complete cytogenetic response (CCR) was achieved by five of nine and two of nine patients, respectively. However, ruxolitinib was stopped in eight of nine patients because of primary resistance (n = 3), progression (n = 3) or planned allogeneic stem cell transplantation (allo SCT, n = 2). At a median of 36 months (range 4-78 months) from diagnosis, five of nine patients are alive: four of six patients after allo SCT and one patient who remains on ruxolitinib. In ETV6-ABL1 positive patients, a durable CHR was achieved by four of nine patients (imatinib with one of five, nilotinib with two of three, dasatinib with one of one). Because of inadequate efficacy (lack of hematological and/or cytogenetic/molecular response), six of nine patients (imatinib, n = 5; nilotinib, n = 1) were switched to nilotinib or dasatinib. At a median of 23 months (range 3-60 months) from diagnosis, five of nine patients are in CCR or complete molecular response (nilotinib, n = 2; dasatinib, n = 2; allo SCT, n = 1) while two of nine patients have died. We conclude that (a) responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and (b) nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6-ABL1 positive patients.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Naumann, Nicole</subfield><subfield code="d">1988-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1138951838</subfield><subfield code="0">(DE-627)896569624</subfield><subfield code="0">(DE-576)49279314X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lübke, Johannes</subfield><subfield code="d">1996-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1189769867</subfield><subfield code="0">(DE-627)1668483645</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jawhar, Mohamad</subfield><subfield code="d">1986-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1046172905</subfield><subfield code="0">(DE-627)775847747</subfield><subfield code="0">(DE-576)399437061</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Somervaille, Tim C.P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Williams, Mark S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Frewin, Rebecca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jost, Philipp J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lichtenegger, Felix S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">La Rosée, Paul</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Storch, Nicola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haferlach, Torsten</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Horny, Hans-Peter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fabarius, Alice</subfield><subfield code="d">1965-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1037001281</subfield><subfield code="0">(DE-627)751728314</subfield><subfield code="0">(DE-576)390896667</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haferlach, Claudia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Burchert, Andreas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hofmann, Wolf-Karsten</subfield><subfield code="d">1967-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)114154635</subfield><subfield code="0">(DE-627)691208751</subfield><subfield code="0">(DE-576)351568336</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cross, Nicholas C.P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hochhaus, Andreas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reiter, Andreas</subfield><subfield code="d">1964-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)172629551</subfield><subfield code="0">(DE-627)697563766</subfield><subfield code="0">(DE-576)133488594</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Metzgeroth, Georgia</subfield><subfield code="d">1972-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1051897661</subfield><subfield code="0">(DE-627)786986832</subfield><subfield code="0">(DE-576)407534075</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">American journal of hematology</subfield><subfield code="d">New York, NY : Wiley-Liss, 1976</subfield><subfield code="g">95(2020), 7 vom: Apr., Seite 824-833</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)302923349</subfield><subfield code="w">(DE-600)1492749-4</subfield><subfield code="w">(DE-576)094060002</subfield><subfield code="x">1096-8652</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:95</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:7</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:824-833</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/ajh.25825</subfield><subfield code="x">Verlag</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ISIL_DE-16</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_1</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_KXP</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_266</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_647</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2013</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2403</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2013</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ISIL_DE-16-250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2403</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ISIL_DE-LFER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">95</subfield><subfield code="j">2020</subfield><subfield code="e">7</subfield><subfield code="c">4</subfield><subfield code="h">824-833</subfield><subfield code="g">10</subfield></datafield><datafield tag="980" ind1=" " ind2=" "><subfield code="2">2011</subfield><subfield code="1">01</subfield><subfield code="x">DE-16</subfield><subfield code="b">4039864360</subfield><subfield code="c">00</subfield><subfield code="f">--%%--</subfield><subfield code="d">--%%--</subfield><subfield code="e">--%%--</subfield><subfield code="j">--%%--</subfield><subfield code="y">l01</subfield><subfield code="z">20-01-22</subfield></datafield><datafield tag="980" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="b">4045645756</subfield><subfield code="c">00</subfield><subfield code="f">--%%--</subfield><subfield code="d">--%%--</subfield><subfield code="e">--%%--</subfield><subfield code="j">--%%--</subfield><subfield code="y">l01</subfield><subfield code="z">27-01-22</subfield></datafield><datafield tag="980" ind1=" " ind2=" "><subfield code="2">2403</subfield><subfield code="1">01</subfield><subfield code="x">DE-LFER</subfield><subfield code="b">4052889959</subfield><subfield code="c">00</subfield><subfield code="f">--%%--</subfield><subfield code="d">--%%--</subfield><subfield code="e">n</subfield><subfield code="j">--%%--</subfield><subfield code="y">l01</subfield><subfield code="z">08-02-22</subfield></datafield><datafield tag="981" ind1=" " ind2=" "><subfield code="2">2403</subfield><subfield code="1">01</subfield><subfield code="x">DE-LFER</subfield><subfield code="r">https://doi.org/10.1002/ajh.25825</subfield></datafield><datafield tag="981" ind1=" " ind2=" "><subfield code="2">2403</subfield><subfield code="1">01</subfield><subfield code="x">DE-LFER</subfield><subfield code="r">https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25825</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">00</subfield><subfield code="s">s</subfield><subfield code="a">hd2020</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">01</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410508463</subfield><subfield code="a">wissenschaftlicher Artikel (Zeitschrift)</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">02</subfield><subfield code="s">s</subfield><subfield code="a">per_21</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">03</subfield><subfield code="s">s</subfield><subfield code="a">s_10</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1477558896</subfield><subfield code="a">Schwaab, Juliana</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="a">pos_1</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">05</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1562793470</subfield><subfield code="a">Naumann, Nicole</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">05</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">05</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">05</subfield><subfield code="s">s</subfield><subfield code="a">pos_2</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">06</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1668484099</subfield><subfield code="a">Lübke, Johannes</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">06</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">06</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">06</subfield><subfield code="s">s</subfield><subfield code="a">pos_3</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">07</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1482083817</subfield><subfield code="a">Jawhar, Mohamad</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">07</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">07</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">07</subfield><subfield code="s">s</subfield><subfield code="a">pos_4</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">08</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1460939530</subfield><subfield code="a">Fabarius, Alice</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">08</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">08</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">08</subfield><subfield code="s">s</subfield><subfield code="a">pos_14</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">09</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1448669421</subfield><subfield code="a">Hofmann, Wolf-Karsten</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">09</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">09</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">09</subfield><subfield code="s">s</subfield><subfield code="a">pos_17</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">10</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1446321282</subfield><subfield code="a">Reiter, Andreas</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">10</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">10</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">10</subfield><subfield code="s">s</subfield><subfield code="a">pos_20</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">11</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1477558845</subfield><subfield code="a">Metzgeroth, Georgia</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">11</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416468528</subfield><subfield code="a">III. Medizinische Klinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">11</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">11</subfield><subfield code="s">s</subfield><subfield code="a">pos_21</subfield></datafield></record></collection>
|
score |
7.401185 |